Harnessing the Power of Antibody-Drug Conjugates for the Treatment of Hematologic and Solid Cancer

Get clinical insights on the latest antibody-drug conjugate treatments for patients with cancer.
Seven live monthly webinars accredited for 1 AMA PRA Category 1 Credit TM

Course Director

Sara Hurvitz, MD, FACP

Director, Breast Cancer Clinical Trials
Program, Division of Hematology-Oncology,
David Geffen School of Medicine, UCLA
Medical Director, Clinical Research Unit,
Jonsson Comprehensive Cancer Center

Agenda

Welcome, Introductions, and Pre-session Survey
Didactic Presentation of ADCs by Topic/Tumor Type
Polling Questions, and Discussion
Q&A
Conclusion and Post-session Survey

Upcoming Webinars

May 2, 2022

Antibody-Drug Conjugates in Lung Cancer

Benjamin Levy, MD
Clinical Director of Medical Oncology, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital Associate Professor of Oncology

June 6, 2022

Recent Advances of Antibody-Drug Conjugates in Hematologic Malignancies

Connie Batlevi, MD, PhD

Inpatient Clinical Director of Lymphoma Service Memorial Sloan Kettering Cancer Center

July 18, 2022

The Promise of Antibody-Drug Conjugates in Gynecologic Malignancies

Bhavana Pothuri, MD
Professor, Department of Obstetrics and Gynecology and Medicine.
Director, Gynecologic Oncology Clinical Trials
NYU Grossman School of Medicine.